chr16-1220227-G-A
Variant summary
Our verdict is Benign. The variant received -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2
The NM_021098.3(CACNA1H):c.6295G>A(p.Glu2099Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0000139 in 1,580,368 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E2099D) has been classified as Likely benign.
Frequency
Consequence
NM_021098.3 missense
Scores
Clinical Significance
Conservation
Publications
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -7 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_021098.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | NM_021098.3 | MANE Select | c.6295G>A | p.Glu2099Lys | missense | Exon 35 of 35 | NP_066921.2 | ||
| CACNA1H | NM_001005407.2 | c.6277G>A | p.Glu2093Lys | missense | Exon 34 of 34 | NP_001005407.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | ENST00000348261.11 | TSL:1 MANE Select | c.6295G>A | p.Glu2099Lys | missense | Exon 35 of 35 | ENSP00000334198.7 | ||
| CACNA1H | ENST00000569107.6 | TSL:1 | c.6310G>A | p.Glu2104Lys | missense | Exon 34 of 34 | ENSP00000454990.2 | ||
| CACNA1H | ENST00000711493.1 | c.6280G>A | p.Glu2094Lys | missense | Exon 34 of 34 | ENSP00000518778.1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152184Hom.: 0 Cov.: 35 show subpopulations
GnomAD2 exomes AF: 0.0000145 AC: 3AN: 207340 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.0000126 AC: 18AN: 1428184Hom.: 0 Cov.: 73 AF XY: 0.0000113 AC XY: 8AN XY: 709576 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152184Hom.: 0 Cov.: 35 AF XY: 0.00 AC XY: 0AN XY: 74350 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
The c.6295G>A (p.E2099K) alteration is located in exon 35 (coding exon 34) of the CACNA1H gene. This alteration results from a G to A substitution at nucleotide position 6295, causing the glutamic acid (E) at amino acid position 2099 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at